Founder | CEO @ DM Consulting Services | Advisor | The Top Leaders of 2024 "Women We Admire" National Edition, CT & MA | Cell & Gene Therapy Commercial Expert.
This article on #StemCellTherapy for Crohn’s and ulcerative colitis caught my attention! It shows the field is finally catching up to a vision many of us have been pushing toward for years: regeneration over suppression. #Biotech https://t.co/nYXrBTnFts
The rules of the game have changed. Investors aren’t just betting on data; they’re betting on speed, positioning, and regulatory foresight. And in a climate where FDA timelines are shifting sand, that matters more than ever. #Biotech
@andrew__rea Well said! Being in touch with your emotions is actually such an important part of being a founder. If you have unchecked fear, anxiety, or insecurity and you're not sure where those feelings are coming from or how to manage them, it can have a major impact on your business.
Spoiler: Innovation without infrastructure rarely scales. Big thanks to @Pinchforthx for highlighting my thoughts on the future of BioTech, startups, and mentorship. You can check out the full piece below!
#Biotech founders: if you’re waiting to think about strategy after your science matures, you’re already behind. Too many promising therapies get stuck in the “great idea” phase because commercial development is treated like an afterthought. 🧵 https://t.co/V9b9dPzSac
Innovation without clarity is just noise. If your organization, conference, or leadership summit is ready for a dose of real talk, I’m here for it. And if you’re more of a reader than a listener? My bestselling book #RiseAboveTheNoise is a great place to start.
Most of the founders I work with are PhDs: visionary, highly skilled, and armed with game-changing ideas. But launching a #BiotechStartup is more than just a scientific challenge. That early phase? It’s messy. You need more than a breakthrough. You need a blueprint.
@DanielPriestley Great startup advice, Daniel. Structure is one of the most important parts of a sustainable startup. And you have to understand what success and stability look like for you before you can design that structure.
The FDA’s move to eliminate REMS for approved CAR T-cell therapies is a bold step toward democratizing access to potentially curative treatments. For #startups navigating this landscape, it’s a signal to think differently about how you’re enabling care. https://t.co/jCkYIRl2jX
In biotech, everything moves: science, regulation, funding cycles, and your own perspective. The people who win aren’t the ones clinging to what they used to know. It’s the ones who are willing to evolve, learn fast, and make bold moves before the data is fully in.
Starting over isn’t failure. It’s strategy. When I left a secure role in #biopharma to start DM Biotech Consulting, I didn’t have all the answers. What I did have was this:
A lot of #BiotechStartups hit the same wall. Great science, no roadmap. That’s where DM Biotech Consulting steps in. We specialize in early-stage strategy for founders with big ideas and small budgets. Check out our site to learn more. #Biotech https://t.co/zuSNojOGLw
In #biotech (and in life), your next opportunity isn’t always found in a pitch deck. It’s in the people you’re bold enough to meet. And that's something you can't automate or outsource... It's something you have to build person by person. @AmThoughtLeader
@TheEmilyHart As a founder, I've been through the trial and error of trying to manage a schedule that feels overwhelming. I've found blocking off the larger chunks of time has been more productive for me, too.
25 years ago, non-invasive #CellTherapy for solid tumors sounded like sci-fi. Now? Moffitt & cTRL Therapeutics are making it real. Bold science and pragmatic development equals wins for patients AND the ecosystem. https://t.co/mWyb9btD99
Big thanks to Dominic Forth + Thought Leaders America for having me on Momentum 50: Founders To Watch in 2025. Grateful to share the story behind Rise Above the Noise—and the “why” driving the work. 🎙️
#RiseAboveTheNoise#Momentum50#Leadership#FoundersToWatch
#Biotech funding in 2025 is hitting nearly $27B but is increasingly concentrated in fewer companies. Investors favor those with strong #ClinicalData, while early-stage and platform biotechs face funding challenges amid a more selective investment climate.
The #biologics#CDMO market is booming, set to hit $93B by 2034. As therapies grow complex, strategic CDMO partnerships are key, offering expertise, speed, and regulatory support. https://t.co/qt579tQWEb